USPTO 2015–2025 USPTO PatentsView US Corporation

Alnylam Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 287 granted patents across 23 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

RSS updates for this company

The verdict

According to USPTO PatentsView, Alnylam ranks #1,451 of 49,997 tracked US assignees by granted-patent volume, with 287 patents across 23 technology areas.

#1,451
of 49,997 US assignees by volume
Top 6%
by Innovation Score (56.4/100)
26.0
avg claims per patent
+2%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1451 · US Corporation #1,451 · 287 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-FLAT · BOOK-FULL

  • GRANTS-MID 287 grants
  • TOP-DECILE #1,451/49,997
  • PHOTO-FINISH Carl Freudenberg KG
  • CPC-FOCUS C12N · 23 areas
  • INNOV-PAR 56.4/100
  • CLAIMS-DENSE 26.0 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-FLAT +2% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Carl Freudenberg KG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Alnylam

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Alnylam's Innovation Score is 56.4/100 (top 6% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Alnylam's grants concentrate

Alnylam Pharmaceuticals, Inc. is a focused PatentsView assignee: 23 CPC subclasses with 91.3% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2015 (42 grants) versus a trough of 17 in 2017. By volume, Alnylam sits between Julius Blum GMBH and Jiaxing Super Lighting Electric Appliance Co., Ltd.

Alnylam's three-year grant acceleration

From 2019–2021 to 2022–2024, Alnylam Pharmaceuticals, Inc. moved from 93 to 68 grants (0.73x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,046. See the growth leaderboard.

Who files at Alnylam's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Alnylam holds 287 patents at rank #1,451, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Alnylam

By rank, the assignees closest to #1,451 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Alnylam's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Alnylam, neither rank-band nor same-CPC leaders (those blocks stay above).

Alnylam's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

56 Top 6% higher than 94% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

1020304050 20152016201720182019202020212022202320242025 21
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Alnylam Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 42 14.6%
2016 24 8.4%
2017 17 5.9%
2018 22 7.7%
2019 27 9.4%
2020 25 8.7%
2021 41 14.3%
2022 26 9.1%
2023 18 6.3%
2024 24 8.4%
2025partial year 21 7.3%

Which technologies does Alnylam Pharmaceuticals, Inc. patent most?

Top 15 of 23 technology areas

Where it ranks

Overall rank by patents

#1,451

of 49,997 tracked assignees

Innovation Score

56.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Alnylam Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

  • Alnylam Pharmaceuticals, Inc.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 91.3% of its portfolio - see every assignee active in that class. Explore C12N
  • Ranked #1,451 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Alnylam Pharmaceuticals, Inc. against Julius Blum GMBH, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 56.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.